|Bid||70.64 x 1100|
|Ask||70.84 x 1100|
|Day's Range||70.10 - 75.56|
|52 Week Range||14.80 - 126.90|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Beam Therapeutics Inc. (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2021 investor letter – a copy of which can be downloaded here. A return of 0.58% was delivered by the fund’s institutional shares for the Q1 of 2021, below both its S&P 500 and Russell 3000 Health Care benchmarks that delivered a […]
Intellia Therapeutics (NASDAQ: NTLA), Beam Therapeutics (NASDAQ: BEAM), and Twist Bioscience (NASDAQ: TWST) are all carving niches for themselves in that industry, adding to what we know about the human genome and using that knowledge in an attempt to fight some of the most stubborn diseases. Genetic medicine is a broad field, but ultimately it comes down to a relatively simple premise.